Biotest Sustainability Profile
Biotest AG, a leading player in the biopharmaceutical industry, is headquartered in Dreieich, Germany. Founded in 1946, the company has established itself as a pioneer in the development and production of immunoglobulins and blood plasma products. With a strong focus on therapeutic areas such as immunology and haematology, Biotest is committed to enhancing patient care through innovative solutions. The company’s core offerings include high-quality plasma-derived therapies, which are distinguished by their rigorous quality standards and advanced manufacturing processes. Biotest has achieved significant milestones, including the expansion of its global presence, with operations spanning Europe, North America, and Asia. Renowned for its commitment to research and development, Biotest continues to solidify its market position as a trusted provider of essential biopharmaceuticals, contributing to improved health outcomes worldwide.
DitchCarbon Score
How does Biotest's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Biotest's score of 42 is higher than 61% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Biotest's reported carbon emissions
In 2022, Biotest reported total carbon emissions of approximately 18,185,600 kg CO2e from Scope 1 and 930,500 kg CO2e from Scope 2, resulting in a combined total of about 19,116,100 kg CO2e. This data reflects a significant increase compared to 2021, when total emissions were approximately 2,054,400 kg CO2e, with Scope 1 emissions contributing about 1,129,500 kg CO2e and Scope 2 emissions at approximately 711,000 kg CO2e. Biotest's emissions data is cascaded from its parent company, Biotest Aktiengesellschaft, which is part of the corporate family of Grifols, S.A. This relationship influences their sustainability initiatives and reporting practices. However, there are currently no specific reduction targets or climate pledges documented for Biotest, indicating a potential area for future commitment. The company has not disclosed any Scope 3 emissions data, which typically encompasses indirect emissions from the supply chain and product use. As such, Biotest's climate commitments and strategies may need further development to align with industry standards and expectations for comprehensive emissions reporting and reduction initiatives.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2021 | 2022 | |
|---|---|---|---|
| Scope 1 | 893,000 | 0,000,000 | 00,000,000 |
| Scope 2 | 16,537,200 | 000,000 | 000,000 |
| Scope 3 | - | - | - |
How Carbon Intensive is Biotest's Industry?
How Carbon Intensive is Biotest's Location?
Biotest's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Biotest has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
